【摘要】 目的研究莫西沙星治疗急性细菌性鼻窦炎的临床疗效和安全性。方法将80例急性细菌性鼻窦炎患者随机分为莫西沙星治疗组(治疗组,n=40)和克拉霉素对照组(对照组,n=40)进行治疗。结果莫西沙星组有效率为97.5%,细菌清除率为81.5%;克拉霉素组有效率为90.0%,细菌清除率为80.8%。莫西沙星组有效率优于克拉霉素组(P<0.05),两组细菌清除率差异无统计学意义(P>0.05)。结论莫西沙星具有双重靶位作用,是安全有效的氟喹诺酮类药物,可以作为急性细菌性鼻窦炎经验性治疗的选择。更多还原

【Abstract】 Objective To study clinical efficacy and safety of moxifloxacin in the treatment of acute bacterial rhinosinusitis.Methods Eighty cases of acute bacterial rhinosinusitis were randomly divided into moxifloxacin treatment group(treatment group,n = 40) and clarithromycin treatment group(control group,n = 40).Results The effective rate of Moxifloxacin group was 97.5%,bacterial clearance rate was 81.5%;The effective rate of Clarithromycin group was 90.0%,bacterial clearance rate was 80.8%.The effective rate of Moxifloxacin group was better than that of Clarithromycin group(P < 0.05),the difference of two groups in bacteria clearance rate was not statistically significant(P > 0.05).Conclusion Moxifloxacin has a dual target role,it is the fluoroquinolone class drug with safe and effective,which can be used as a treatment choice of acute bacterial rhinosinusitis.更多还原